WHO gives emergency approval to Sinopharm, first Chinese COVID-19 vaccine

By: |
May 07, 2021 9:01 PM

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

Chinese COVID-19 vaccine SinopharmThe vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO's backing.

The World Health Organization (WHO) announced on Friday it had approved a COVID-19 vaccine from China’s state-owned drugmaker Sinopharm for emergency use.

The vaccine, one of two main Chinese shots that collectively have already been given to hundreds of millions of people in China and abroad, becomes the first COVID-19 shot developed by a non-Western country to win the WHO’s backing.

It is also the first time the WHO has given emergency use approval to any Chinese vaccine for any infectious disease.

A WHO emergency listing is a signal to national regulators on a product’s safety and efficacy, and would allow the shot to be included in COVAX, the global programme to provide vaccines mainly for poor countries.

The WHO has previously given emergency approval to COVID-19 vaccines developed by Pfizer-BioNTech, AstraZeneca, Johnson & Johnson, and, last week, Moderna.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Tamil Nadu lockdown update: Bus, Metro Rail services to resume in Chennai; TN govt eases more curbs
2Delhi records 124 new COVID-19 cases, lowest since February 16; positivity rate 0.17 pc
3Haryana extends lockdown till June 28, announces more relaxations